Guideline-Endorsed Answers to Key Questions in Nontuberculous Mycobacterial Lung Disease Management

The emergence of new guidelines requires education that provides physicians with the knowledge to recognize the symptoms and risk factors for nontuberculous mycobacterial lung disease (NTM-LD), to initiate steps for prompt differential diagnosis, to incorporate the patient in understanding disease course and in management, and to select treatment with the safest and most effective antimicrobials.

This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.

Agenda

  • Introduction and preactivity assessment (5 mins)
  • Panel Discussion: Applying Practice Guidelines in the Optimal Management of NTM-LD (45 mins) 
    Case-based panel discussion featuring patient interviews which will navigate key issues and guideline-based strategies for management of NTM-LD.
  • Conclusion and Question and Answer Session (10 mins)

Events

Date / Time
Event Details

Faculty

Program Director
Keira A. Cohen, MD

Assistant Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Johns Hopkins University School of Medicine

Faculty
David E. Griffith, MD

Professor of Medicine
National Jewish Health
Denver, Colorado

Faculty
Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief, 
Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to apply practice guidelines and provide patient-centered care in the diagnosis and management of NTM-LD.

Target Audience
This program is intended for infectious disease and pulmonology physicians, pharmacists, and other healthcare providers who care for patients with NTM-LD.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Utilize appropriate clinical, radiographic, and microbiologic criteria for reducing time to NTM-LD diagnosis and characterization
  • Develop guideline-recommended and evidence-based approaches to the treatment of NTM-LD
  • Identify key issues of importance to patients surrounding their illness symptoms and treatment side effects
  • In partnership with patients, provide individualized and comprehensive treatment plans for NTM-LD

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. UAN: JA4008176-0000-21-179-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.